The gap between the stock purchase price and the cost will be a point of legal review after taking convertible notes into consideration. Clearly, management enriched themselves with excess stock options, which are frequently sold ahead of the the deal to avoid the obvious conflict of interest. Five years from now, I expect to see a check for 5 dollars from a class action suit, especially after the breast cancer results are announced and Pfizer's compound is pulling down a 7 billion a year. Kudo's to the stock gyration guy who sold at 134. Do you ever short?